Eli Lilly (LLY) Slides After Its Experimental Breast Cancer Drug Fails
October 01, 2013 at 10:07 AM EDT
Shares of pharma giant Eli Lilly (LLY) tumbled last week, after the company reported that it would not seek breast cancer approval for ramucirumab, its experimental cancer treatment which has also been tested on gastric, colon, liver, and lung cance... Read the rest of Eli Lilly (LLY) Slides After Its Experimental Breast Cancer Drug Fails at InvestorGuide.com .
